In Vivo Administration of a JAK3 Inhibitor to Chronically SIV Infected Rhesus Macaques Leads to NK Cell Depletion Associated with Transient Modest Increase in Viral Loads

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Takahashi, Yoshiaki ^a   Mayne, Ann E ^a   Khowawisetsut, Ladawan ^b   Pattanapanyasat, Kovit ^b   Little, Dawn ^a   Villinger, Francois ^c   Ansari, Aftab A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 17; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; NATURAL KILLER CELL RECEPTOR NKG2A; STAT5 PROTEIN; TOFACITINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD CELL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL LINEAGE; CYTOKINE PRODUCTION; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL MUCOSA; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MALE; NATURAL KILLER CELL; NONHUMAN; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LOAD;

ANIMALS; CHRONIC DISEASE; JANUS KINASE 3; KILLER CELLS, NATURAL; MACACA MULATTA; MALE; PROTEIN KINASES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

EID: 84880787188     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070992     Document Type: Article

References (87)

1. Ansari AA, Mayne AE, Takahashi Y, Pattanapanyasat K, (2011) Incorporation of innate immune effector mechanisms in the formulation of a vaccine against HIV-1. Adv Exp Med Biol 780: 143-159.
2. Centlivre M, Sala M, Wain-Hobson S, Berkhout B, (2007) In HIV-1 pathogenesis the die is cast during primary infection. AIDS 21: 1-11.
3. Haase AT, (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464: 217-223.
4. Prince JL, Claiborne DT, Carlson JM, Schaefer M, Yu T, et al. (2012) Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog 8: e1003041.
5. Breed MW, Jordan AP, Aye PP, Lichtveld CF, Midkiff CC, et al. (2013) Loss of a tyrosine-dependent trafficking motif in the simian immunodeficiency virus envelope cytoplasmic tail spares mucosal CD4 cells but does not prevent disease progression. J Virol 87: 1528-1543.
6. Khowawisetsut L, Pattanapanyasat K, Onlamoon N, Mayne AE, Little DM,et al. (2013) Relationships between IL-17+ subsets, Tregs and pDCs that distinguish among SIV infected elite controllers, low, medium and high viral load rhesus macaques1. PlosOne In Press.
7. Letvin NL, Rao SS, Dang V, Buzby AP, Korioth-Schmitz B, et al. (2007) No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys. J Virol 81: 12368-12374.
8. Marthas ML, Lu D, Penedo MC, Hendrickx AG, Miller CJ, (2001) Titration of an SIVmac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: transmission efficiency, viral loads, and antibody responses. AIDS Res Hum Retroviruses 17: 1455-1466.
9. Staprans SI, Dailey PJ, Rosenthal A, Horton C, Grant RM, et al. (1999) Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol 73: 4829-4839.
10. Caligiuri MA, (2008) Human natural killer cells. Blood 112: 461-469.
11. Jost S, Altfeld M (2013) Control of Human Viral Infections by Natural Killer Cells. Annu Rev Immunol.
12. Bezman NA, Chakraborty T, Bender T, Lanier LL, (2011) miR-150 regulates the development of NK and iNKT cells. J Exp Med 208: 2717-2731.
13. Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, et al. (2009) Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol 10: 66-74.
14. Eissens DN, Spanholtz J, van der Meer A, van Cranenbroek B, Dolstra H, et al. (2012) Defining early human NK cell developmental stages in primary and secondary lymphoid tissues. PLoS One 7: e30930.
15. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, et al. (2006) Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 203: 1033-1043.
16. Haraguchi K, Suzuki T, Koyama N, Kumano K, Nakahara F, et al. (2009) Notch activation induces the generation of functional NK cells from human cord blood CD34-positive cells devoid of IL-15. J Immunol 182: 6168-6178.
17. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, et al. (2009) IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 206: 25-34.
18. Kamizono S, Duncan GS, Seidel MG, Morimoto A, Hamada K, et al. (2009) Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J Exp Med 206: 2977-2986.
19. Sun JC, Lanier LL, (2011) NK cell development, homeostasis and function: parallels with CD8(+) T cells. Nat Rev Immunol 11: 645-657.
20. Vargas CL, Poursine-Laurent J, Yang L, Yokoyama WM, (2011) Development of thymic NK cells from double negative 1 thymocyte precursors. Blood 118: 3570-3578.
21. Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, et al. (2007) The trafficking of natural killer cells. Immunol Rev 220: 169-182.
22. Li N, Puga Yung GL, Pradier A, Toso C, Giostra E, et al. (2013) NK cell isolation from liver biopsies: phenotypic and functional analysis of low cell numbers by flow cytometry. Front Immunol 4: 61.
23. Pereira LE, Johnson RP, Ansari AA, (2008) Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection. Cell Immunol 254: 10-19.
24. Reeves RK, Rajakumar PA, Evans TI, Connole M, Gillis J, et al. (2011) Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection. Blood 118: 3321-3330.
25. Fauriat C, Long EO, Ljunggren HG, Bryceson YT, (2010) Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 115: 2167-2176.
26. Strowig T, Brilot F, Munz C, (2008) Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol 180: 7785-7791.
27. Deniz G, Erten G, Kucuksezer UC, Kocacik D, Karagiannidis C, et al. (2008) Regulatory NK cells suppress antigen-specific T cell responses. J Immunol 180: 850-857.
28. Ehlers M, Papewalis C, Stenzel W, Jacobs B, Meyer KL, et al. (2012) Immunoregulatory natural killer cells suppress autoimmunity by down-regulating antigen-specific CD8+ T cells in mice. Endocrinology 153: 4367-4379.
29. Fu B, Li X, Sun R, Tong X, Ling B, et al. (2013) Natural killer cells promote immune tolerance by regulating inflammatory TH17 cells at the human maternal-fetal interface. Proc Natl Acad Sci U S A 110: E231-240.
30. Ge MQ, Ho AW, Tang Y, Wong KH, Chua BY, et al. (2012) NK cells regulate CD8+ T cell priming and dendritic cell migration during influenza A infection by IFN-gamma and perforin-dependent mechanisms. J Immunol 189: 2099-2109.
31. Jewett A, Man YG, Tseng HC, (2013) Dual functions of natural killer cells in selection and differentiation of stem cells; role in regulation of inflammation and regeneration of tissues. J Cancer 4: 12-24.
32. Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA, et al. (2012) Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A 109: 1210-1215.
33. Waggoner SN, Cornberg M, Selin LK, Welsh RM, (2012) Natural killer cells act as rheostats modulating antiviral T cells. Nature 481: 394-398.
34. Paust S, von Andrian UH, (2011) Natural killer cell memory. Nat Immunol 12: 500-508.
35. Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, et al. (2012) Cytokine activation induces human memory-like NK cells. Blood 120: 4751-4760.
36. Zhang T, Scott JM, Hwang I, Kim S, (2013) Cutting Edge: Antibody-Dependent Memory-like NK Cells Distinguished by FcRgamma Deficiency. J Immunol 190: 1402-1406.
37. Cooper MA, Yokoyama WM, (2010) Memory-like responses of natural killer cells. Immunol Rev 235: 297-305.
38. Elliott JM, Yokoyama WM, (2011) Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol 32: 364-372.
39. Jonsson AH, Yokoyama WM, (2009) Natural killer cell tolerance licensing and other mechanisms. Adv Immunol 101: 27-79.
40. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, et al. (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436: 709-713.
41. Paust S, Gill HS, Wang BZ, Flynn MP, Moseman EA, et al. (2010) Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol 11: 1127-1135.
42. Mace EM, Orange JS, (2012) New views of the human NK cell immunological synapse: recent advances enabled by super- and high-resolution imaging techniques. Front Immunol 3: 421.
43. Murphy WJ, Parham P, Miller JS, (2012) NK cells-from bench to clinic. Biol Blood Marrow Transplant 18: S2-7.
44. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, et al. (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
45. Krueger PD, Lassen MG, Qiao H, Hahn YS, (2011) Regulation of NK cell repertoire and function in the liver. Crit Rev Immunol 31: 43-52.
46. Xu H, Wang X, Liu DX, Moroney-Rasmussen T, Lackner AA, et al. (2012) IL-17-producing innate lymphoid cells are restricted to mucosal tissues and are depleted in SIV-infected macaques. Mucosal Immunol 5: 658-669.
47. Hosoya S, Ikejima K, Takeda K, Arai K, Ishikawa S, et al. (2013) Innate immune responses involving natural killer and natural killer T cells promote liver regeneration after partial hepatectomy in mice. Am J Physiol Gastrointest Liver Physiol 304: G293-299.
48. Kumar P, Rajasekaran K, Palmer JM, Thakar MS, Malarkannan S, (2013) IL-22: An Evolutionary Missing-Link Authenticating the Role of the Immune System in Tissue Regeneration. J Cancer 4: 57-65.
49. Hall LJ, Clare S, Dougan G, (2010) NK cells influence both innate and adaptive immune responses after mucosal immunization with antigen and mucosal adjuvant. J Immunol 184: 4327-4337.
50. Nishikado H, Mukai K, Kawano Y, Minegishi Y, Karasuyama H, (2011) NK cell-depleting anti-asialo GM1 antibody exhibits a lethal off-target effect on basophils in vivo. J Immunol 186: 5766-5771.
51. Winkler-Pickett R, Young HA, Cherry JM, Diehl J, Wine J, et al. (2008) In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J Immunol 180: 4495-4506.
52. Biron CA, Byron KS, Sullivan JL, (1989) Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 320: 1731-1735.
53. Orange JS, (2002) Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect 4: 1545-1558.
54. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM, (2000) In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A 97: 2731-2736.
55. Albright JW, Albright JF, (1985) Age-associated decline in natural killer (NK) activity reflects primarily a defect in function of NK cells. Mech Ageing Dev 31: 295-306.
56. Cook KD, Whitmire JK, (2013) The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection. J Immunol 190: 641-649.
57. Pachynski RK, Zabel BA, Kohrt HE, Tejeda NM, Monnier J, et al. (2012) The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J Exp Med 209: 1427-1435.
58. Raziuddin A, Bennett M, Winkler-Pickett R, Ortaldo JR, Longo DL, et al. (2000) Synergistic effects of in vivo depletion of Ly-49A and Ly-49G2 natural killer cell subsets in the rejection of H2(b) bone marrow cell allografts. Blood 95: 3840-3844.
59. Scott P, Trinchieri G, (1995) The role of natural killer cells in host-parasite interactions. Curr Opin Immunol 7: 34-40.
60. Trinchieri G, (1989) Biology of natural killer cells. Adv Immunol 47: 187-376.
61. Yokoyama WM (2008) Natural killer cells. In: Paul WE, editor. Fundamental Immunology. New York: Lippincott-Raven. 483-517.
62. Yamada Y, Aoyama A, Tocco G, Boskovic S, Nadazdin O, et al. (2012) Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates. J Immunol 188: 6063-6070.
63. Choi EI, Reimann KA, Letvin NL, (2008) In vivo natural killer cell depletion during primary simian immunodeficiency virus infection in rhesus monkeys. J Virol 82: 6758-6761.
64. Choi EI, Wang R, Peterson L, Letvin NL, Reimann KA, (2008) Use of an anti-CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques. Immunology 124: 215-222.
65. Paniagua R, Si MS, Flores MG, Rousvoal G, Zhang S, et al. (2005) Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 80: 1283-1292.
66. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, et al. (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186: 4234-4243.
67. Soth M, Hermann JC, Yee C, Alam M, Barnett JW, et al. (2013) 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models. J Med Chem 56: 345-356.
68. Kiu H, Nicholson SE, (2012) Biology and significance of the JAK/STAT signalling pathways. Growth Factors 30: 88-106.
69. O'Shea JJ, Plenge R, (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36: 542-550.
70. Conklyn M, Andresen C, Changelian P, Kudlacz E, (2004) The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol 76: 1248-1255.
71. Ansari AA, Reimann KA, Mayne AE, Takahashi Y, Stephenson ST, et al. (2011) Blocking of alpha4beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol 186: 1044-1059.
72. Paniagua R, Campbell A, Changelian PS, Reitz BA, Prakash C, et al. (2005) Quantitative analysis of the immunosuppressant CP-690,550 in whole blood by column-switching high-performance liquid chromatography and mass spectrometry detection. Ther Drug Monit 27: 608-616.
73. Harrison DA (2012) The Jak/STAT pathway. Cold Spring Harb Perspect Biol 4.
74. Usharauli D, Perez-Diez A, Matzinger P, (2006) The JAM Test and its daughter P-JAM: simple tests of DNA fragmentation to measure cell death and stasis. Nat Protoc 1: 672-682.
75. Borie DC, Larson MJ, Flores MG, Campbell A, Rousvoal G, et al. (2005) Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. Transplantation 80: 1756-1764.
76. Borie DC, O'Shea JJ, Changelian PS, (2004) JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol Med 10: 532-541.
77. van Gurp E, Weimar W, Gaston R, Brennan D, Mendez R, et al. (2008) Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant 8: 1711-1718 doi:-1710.1111/j.1600-6143.2008.02307.x. Epub 02008 Jun 02328.
78. Dymock BW, See CS, (2013) Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012. Expert Opin Ther Pat 23: 449-501 doi:410.1517/13543776.13542013.13765862. Epub 13542013 Feb 13543771.
79. Pereira LE, Ansari AA, (2009) A case for innate immune effector mechanisms as contributors to disease resistance in SIV-infected sooty mangabeys. Curr HIV Res 7: 12-22.
80. Stark GR, Darnell JE Jr, (2012) The JAK-STAT pathway at twenty. Immunity 36: 503-514 doi:510.1016/j.immuni.2012.1003.1013.
81. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, et al. (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64: 617-629 doi:610.1002/art.33383.
82. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, et al. (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60: 1895-1905 doi:1810.1002/art.24567.
83. Poli A, Michel T, Theresine M, Andres E, Hentges F, et al. (2009) CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126: 458-465.
84. Hong HS, Eberhard JM, Keudel P, Bollmann BA, Ahmad F, et al. (2010) Phenotypically and functionally distinct subsets contribute to the expansion of CD56-/CD16+ natural killer cells in HIV infection. AIDS 24: 1823-1834.
85. Naranbhai V, Altfeld M, Karim SS, Ndung'u T, Karim QA, et al. (2013) Changes in Natural Killer cell activation and function during primary HIV-1 Infection. PLoS One 8: e53251.
86. Bostik P, Takahashi Y, Mayne AE, Ansari AA, (2010) Innate immune natural killer cells and their role in HIV and SIV infection. HIV Ther 4: 483-504.
87. Albrecht C, Brameier M, Hermes M, Ansari AA, Walter L (2013) Progression to AIDS in SIV-infected rhesus macaques is associated with distinct KIR and MHC class I gene polymorphisms and changes of KIR-positive gamma delta T cells in blood. PLoS Pathog Submitted.